Paul Gross Net Worth 2024

Paul Gross Net Worth As of June 17, 2024, the estimated net worth of Paul Gross is at least $1,475. Paul Gross serves as See Remarks at Clovis Oncology Inc and holds approximately 98,330 shares of Clovis Oncology Inc (CLVSQ) stock, valued at over $1,475. These details are based on the most recent information available and reflect holdings up to the date of November 2, 2022.

Disclaimer: The insider information presented here is derived from SEC filings. The estimated net worth assumes that Paul Gross has not made any further transactions post November 2, 2022, and currently retains the listed stock(s).

Paul Gross Insider Ownership Reports

Paul Gross, as a reporting owner, has his insider ownership documented through SEC filings. According to these reports, he owns stock in one company: Clovis Oncology Inc (CLVSQ).

For an exhaustive history of Paul Gross’s Form 4 insider trades, you can click here.

Insider Ownership Summary of Paul Gross

Paul Gross Latest Holdings Summary

As of November 2, 2022, Paul Gross holds a total of 98,330 shares in Clovis Oncology Inc (CLVSQ). The current value of these holdings is estimated to be $1,475 based on the latest stock price.

Deep Dive into Paul Gross’s Financial Background

Paul Gross’s financial involvement in Clovis Oncology Inc is notable, given his significant shareholding in the company. Clovis Oncology Inc (ticker: CLVSQ) is a biopharmaceutical firm focused on developing anti-cancer agents. Gross’s ownership of nearly 100,000 shares is indicative of his confidence in the company’s potential.

Understanding Insider Trading and SEC Filings

Insider trading involves the buying or selling of a company’s stock by someone who has non-public, material information about that stock. Insiders, such as corporate executives, directors, and employees, must report their trades to the Securities and Exchange Commission (SEC). These reports are filed using Form 4, which details the insider’s transactions and current holdings.

Significance of Paul Gross’s Holdings

Paul Gross’s substantial holdings in Clovis Oncology Inc could reflect several strategic insights:

1. Confidence in Company’s Future: His large shareholding suggests a strong belief in the company’s growth prospects and future performance.
2. Influence on Company Strategy: As a significant shareholder, Gross likely has considerable influence over the company’s strategic decisions and direction.
3. Long-term Investment Strategy: The retention of shares since November 2022 indicates a long-term investment approach, which can be viewed positively by other investors and stakeholders.

Overview of Clovis Oncology Inc (CLVSQ)

Clovis Oncology Inc is a biopharmaceutical company dedicated to developing innovative cancer treatments. With a focus on improving the lives of patients battling cancer, the company has been involved in the development of several key drugs aimed at targeting specific types of cancer cells.

Company’s Mission and Achievements

The mission of Clovis Oncology is to advance the care and treatment of cancer patients. The company has achieved significant milestones in its drug development programs, contributing to the advancement of cancer therapy.

Future Outlook and Market Position

The future outlook for Clovis Oncology remains optimistic, with ongoing research and development initiatives aimed at introducing new therapies. The company’s market position is strengthened by its commitment to innovation and the potential for new drug approvals.

Impact of Insider Trading on Company Perception

Insider trading activities are closely monitored by investors as they provide insights into the confidence levels of the company’s top executives. When insiders like Paul Gross hold onto their shares, it often signals their positive outlook on the company’s future. This can influence other investors’ perceptions and decisions, potentially impacting the company’s stock price.

Conclusion

Paul Gross’s estimated net worth of $1,475 and his significant shareholding in Clovis Oncology Inc reflect his substantial investment and confidence in the company’s future. Understanding his insider trading activities and their implications provides valuable insights for investors and stakeholders.